Form of Proxy

MINERALYS THERAPEUTICS, INC.

Notes

BD Client Code:

Client Name:

Number of Shares Held in a BD Nominee Company:

No.	Proposition		For	Against	Abstain
1	Election of Class III Director for a three-year term to expire at the 2029 annual meeting of stockholders: Srinivas Akkaraju, M.D., Ph.D.
2	Election of Class III Director for a three-year term to expire at the 2029 annual meeting of stockholders: Brian Taylor Slingsby, M.D., Ph.D., M.P.H.
3	Election of Class III Director for a three-year term to expire at the 2029 annual meeting of stockholders: Daphne Karydas
4	Ratify the appointment of Ernst & Young LLP as Mineralys Therapeutics, Inc.s independent registered public accounting firm for the fiscal year ending December 31, 2026.